XXVI$^{th}$ International Workshop on Helicobacter and related bacteria in chronic digestive inflammation and gastric cancer

Madrid, Spain
September 12 - 14, 2013

FINAL PROGRAMME
### TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcoming Address</td>
<td>3</td>
</tr>
<tr>
<td>Awardees of the Marshall and Warren Medal</td>
<td>3</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>4</td>
</tr>
<tr>
<td>List of Exhibitors</td>
<td>4</td>
</tr>
<tr>
<td>Committees – Organisation</td>
<td>5</td>
</tr>
<tr>
<td>Workshops of the EHSG</td>
<td>5</td>
</tr>
<tr>
<td>Location Map</td>
<td>6</td>
</tr>
<tr>
<td>Programme at a Glance</td>
<td>7</td>
</tr>
<tr>
<td><strong>Scientific Programme</strong></td>
<td></td>
</tr>
<tr>
<td>- Thursday, September 12</td>
<td>10</td>
</tr>
<tr>
<td>- Friday, September 13</td>
<td>11</td>
</tr>
<tr>
<td>- Saturday, September 14</td>
<td>19</td>
</tr>
<tr>
<td><strong>Scientific Information, Poster Schedule</strong></td>
<td>24</td>
</tr>
<tr>
<td><strong>General Information</strong></td>
<td>26</td>
</tr>
<tr>
<td><strong>Registration Details</strong></td>
<td>28</td>
</tr>
<tr>
<td><strong>Networking Events</strong></td>
<td>28</td>
</tr>
</tbody>
</table>
Dear colleagues and friends,

As President of the European Helicobacter Study Group (EHSG), and on behalf of the organizing committee, I have the pleasure to welcome you to the “XXVIth International Workshop on Helicobacter and Related Bacteria” organized by the EHSG. This Conference is a prestigious conference with nearly thirty years of history in which researchers from all over the world assist and participate sending their most recent and advanced clinical and fundamental laboratory research. The high level and quality of its scientific and academic presentations has been accredited by the European Accreditation Council for Continuing Medical Education, and submitted abstracts are peer-reviewed and selected for poster or oral presentation.

If you are a researcher, either clinical or fundamental, involved in Helicobacter infection, you are going to present your advances and obtain feedback from other groups as well as grabbing new ideas for future projects and potential collaborations. If you are a clinician you will obtain the most updated data on epidemiology, diagnosis and treatment of H. pylori.

We sincerely hope, that you will enjoy the workshop from both the scientific and the social point of view.

Welcome to Madrid!
Bienvenidos a Madrid!

Javier P. Gisbert
President of the European Helicobacter Study Group

AWARDEES OF THE MARSHALL & WARREN MEDAL

2013  Masahiro Asaka, Sapporo, Japan
2012  Richard Hunt, Hamilton, ON, Canada
2011  Samy Cadranel, Brussels, Belgium
2010  Reinhold W. Stockbrügger, Maastricht, The Netherlands
2009  Pelayo Correa, Nashville, TN, United States
2008  Timo Kosunen, Helsinki, Finland
2007  Mike Dixon, Leeds, United Kingdom
2006  Barry Marshall, Perth, Australia & Stanislaw Konturek, Cracow, Poland
ACKNOWLEDGEMENTS

The organisers gratefully acknowledge the support of the following institutions and companies:

**Main Sponsor**

![Eisai Logo](image)

**Other Sponsors**

![Aptalis Logo](image)  
![INFAI Logo](image)  
![INFAI FRANCE SARL Logo](image)  
![INFAI UK Ltd Logo](image)  
![Fischer Analysen Instrumente GmbH Logo](image)  
![Meridian Bioscience Europe Logo](image)  
![MSD Logo](image)  
![Otsuka Logo](image)  

**LIST OF EXHIBITORS**

As per printing date

- Aptalis Pharma SAS, Houdan, France
- Fischer Analysen Instrumente GmbH, Leipzig, Germany
- Meridian Bioscience Europe, Milano, Italy
Local Organizing Committee

President
Javier P. Gisbert, Madrid

Members
J.M. Pájares García, Madrid
X. Calvet, Barcelona
A. Lanas, Zaragoza
F. Mearin, Barcelona
F. Gomollón, Zaragoza
J. Molina-Infante, Cáceres
M. Castro-Fernández, Sevilla
T. Alarcón, Madrid
M.J. Martínez, Madrid
C. González, Barcelona
A. McNicholl, Madrid
T. Parra, Guadalajara

European Helicobacter Study Group (EHSG)

President
Javier P. Gisbert, Spain

Members
Leif P. Andersen, Denmark
Anthony Axon, United Kingdom
Lars Engstrand, Sweden
Giovanni Gasbarrini, Italy
Ernst Kuipers, The Netherlands
José C. Machado, Portugal
Peter Malfertheiner, Germany
Francis Mégraud, France
Colm A. O’Morain, Ireland
Ari P. Ristimäki, Finland
Theodore Rokkas, Greece

Emeritus Members
Michel A.L. Deltenre, Belgium
Pierre Michetti, Switzerland
José M. Pájares García, Spain
Ashley B. Price, United Kingdom
Mario G. Quina, Portugal
Erik A.J. Rauws, The Netherlands
Pentti I. Sipponen, Finland
Torkel M. Wadström, Sweden

Honorary Members
Franco Bazzoli, Italy
James G. Fox, United States
David Y. Graham, United States
Adrian Lee, Australia
Barry Marshall, Australia
Guido N.J. Tytgat, The Netherlands

Corresponding Fellows
Niyaz Ahmed, India
Luis G. Vaz Coelho, Brazil
Toshibo Fujioka, Japan
Hyun Chae Jung, Korea
Varocha Mahachai, Thailand
Yaron Niv, Israel
Shu Dong Xiao, China

Organising Offices

Core Agency
Vienna Medical Academy
Alser Strasse 4
A-1090 Vienna, Austria
Phone: +43 1 405 13 83 0
Fax: +43 1 407 82 74
ehsg2013@medacad.org

Technical Exhibition
MAW
Freyung 6
A-1010 Vienna, Austria
Phone: +43 1 536 63 15
Fax: +43 1 535 60 16
maw@media.co.at

Workshops of the EHSG

- Bordeaux (1988)
- Ulm (1989)
- Toledo (1990)
- Bologna (1991)
- Dublin (1992)
- Brussels (1993)
- Houston (1994)
- Copenhagen (1996)
- Lisbon (1997)
- Budapest (1998)
- Helsinki (1999)
- Rome (2000)
- Strasbourg (2001)
- Athens (2002)
- Vienna (2004)
- Copenhagen (2005)
- Wrocław (2006)
- Istanbul (2007)
- Riga (2008)
- Porto (2009)
- Rotterdam (2010)
- Dublin (2011)
- Ljubljana (2012)
- Madrid (2013)
- Rome (2014)

Next Workshop
Rome, Italy, September 11-13, 2014

www.helicobacter.org
LOCATION MAP

Dean's Building
- Registration, Posters and Stands
- Coffee Breaks and lunch

Pagoda
- Parallel Workshop (W3, W4, W6)

Aula Magna
- Symposia
- Parallel Workshops (W1, W3, W5)

Entrances

Librury

DECANATO

Cafeteria

Pagoda

www.helicobacter.org
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 15.00 – 18.00 hrs | Europe-Far East Symposium  
Aula Magna  

- *H. pylori* genomes in Asian countries, Y. Yamaoka, Oita, Japan  
- Different biological implication of inhibitory TGF-β signaling, Smad7, in gastric mucosal damages according to *H. pylori* infection and NSAID administration, K.B. Hahm, Seoul, Korea  
- A genetic factor associate with *H. pylori* infection, E. Kuipers, Rotterdam, The Netherlands  
- Treatment of *H. pylori* infection in Korea over the last 11 years: Nation-wide survey and Evidence-based approach, J.G. Kim, Seoul, Korea  
- Cellular and molecular determinants of *H. pylori*-induced gastric carcinogenesis, C. Varon, Bordeaux, France  
- Roadmap to eliminate Gastric cancer in Japan, M. Asaka, Sapporo, Japan |
| 19.00 hrs     | Networking Mixer at the Casa de la Panaderia, Plaza Mayor 27 (Main Square)                      |
PROGRAMME AT A GLANCE

Friday, September 13, 2013

08.30 – 09.30 hrs
Opening Conferences

Aula Magna

Structure of the proton-gated urea channel, H. Luecke, Irvine, CA, USA
STAT3 in gastric cancer, A. Giraud, Parkville, Australia
Role of CagY in the functional plasticity of H. pylori type 4 secretion system, J. Solnick, Davis, CA, USA

09.30 – 11.00 hrs
Symposium: Steps towards gastric cancer

Aula Magna

Epidemiological aspects of preneoplastic lesions, C.A. Gonzalez, Barcelona, Spain
Endoscopic assessment of preneoplastic lesions, M. Areia, Coimbra, Portugal
Programming of intestinal metaplasia, M. Rugge, Padova, Italy
Role of microRNA and cancer stem cells in gastric carcinogenesis, H. Suzuki, Tokyo, Japan

11.00 – 11.30 hrs
Coffee break

11.30 – 13.00 hrs
Parallel Workshops 1 – 2

W1 Molecular Genetics & Virulence Factors

Aula Magna

W2 Epidemiology and Pediatrics

Pagoda

13.00 – 13.30 hrs
Lunch

13.30 – 14.30 hrs
Poster Rounds

P01. Microbiology
P02. Molecular genetics and genomics
P03. Virulence factors and pathogenesis
P04. Epidemiology and transmission

P09. Paediatric issues
P10. Diagnosis
P13. Drug resistance
P15. Probiotics

14.30 – 16.00 hrs
Symposium: Treatment of H. pylori infection – Beyond antibiotherapy

Aula Magna

How to predict the outcome of an H. pylori therapy, D. Graham, Houston, TX, USA
Vaccine – problems and perspectives, S. Moss, Providence, RI, USA
Vaccine – current clinical results, P. Malfertheiner, Magdeburg, Germany
Phototherapy – Bringing new light in therapy, D. Garcia-Fresnadillo, Madrid, Spain

16.00 – 16.30 hrs
Coffee break

16.30 – 18.00 hrs
Parallel Workshops 3 – 4

W3 Treatment and Drug Resistance

Aula Magna

W4 Other Helicobacters and Animal Models

Pagoda

20.00 hrs
EHSG Networking Dinner
(Ticket required)

www.helicobacter.org
Saturday, September 14, 2013

08.30–10.00 hrs
Symposium: Animal models for Helicobacter infection
Aula Magna
Mice models of gastric carcinoma, J. Fox, Boston, MA, USA
Mouse model of gastric MALT lymphoma, P. Lehours, Bordeaux, France
The Mongolian gerbil model, Y. Yamaoka, Oita, Japan
Animal models of gastric non-H. pylori Helicobacter infection, B. Flahou, Ghent, Belgium

10.00–10.30 hrs
Coffee break

10.30–12.00 hrs
Parallel Workshops 5 – 6
W5 Gastric Cancer and pre-malignant lesions
Aula Magna
W6 Modulation of Inflammation and Immunity
Pagoda

12.00–12.30 hrs
Lunch

12.30–13.30 hrs
Poster Rounds
P05. Inflammation and host response
P06. Pathology and pathophysiology
P07. Preneoplastic and neoplastic diseases
P08. Oesophageal and extradigestive diseases
P11. Clinical trials and novel treatments
P16. Other Helicobacters
P18. H. pylori and Gastric Cancer

13.30–15.00 hrs
Symposium: The Healthy Stomach Initiative
Aula Magna
The asymptomatic stomach, A. O'Connor, Dublin, Ireland
The infected stomach, F. Bazzoli, Bologna, Italy
Screening for gastric cancer during screening for CRC, M. Selgrad, Magdeburg, Germany
Mass eradication of H. pylori, J.M. Liou, Taipei, Taiwan

15.00–15.30 hrs
Special Lecture
Aula Magna
H. pylori therapy – Beyond Maastricht 4, J. Molina-Infante, Cáceres, Spain

15.30–16.00 hrs
Coffee break

16.00–16.45 hrs
Debate: Should we use pepsinogen for the screening of gastric cancer?
Aula Magna
Yes, F. di Mario, Trevise, Italy
No, X. Calvet, Barcelona, Spain

16.45–17.45 hrs
Closing conferences
Aula Magna
Iron deficiency anemia and gastric carcinogenesis, M.R. Amieva, Palo Alto, CA, USA
Autophagy and H. pylori, N. Jones, Toronto, Canada
Awarding of the Marshall & Warren Medal to Masahiro Asaka, Sapporo, Japan

17.45–18.00 hrs
Presentation of the next meeting Rome, Italy
Closing remarks
Aula Magna
15.00 - 18.00 hrs  Europe-Far East Symposium  
Room:  
Aula Magna

Chair:  
M. Asaka, Japan  
H.C. Jung, Korea  
F. Mégraud, France

Speaking Time:  
25’ + 5’

- **H. pylori genomes in Asian countries**  
  Y. Yamaoka, Oita, Japan

- **Different biological implication of inhibitory TGF-β signaling, Smad7, in gastric mucosal damages according to H. pylori infection and NSAID administration**  
  K.B. Hahm, Seoul, Korea

- **A genetic factor associate with H. pylori infection**  
  E. Kuipers, Rotterdam, The Netherlands

- **Treatment of H. pylori infection in Korea over the last 11 years: Nation-wide survey and Evidence-based approach**  
  J.G. Kim, Seoul, Korea

- **Cellular and molecular determinants of H. pylori-induced gastric carcinogenesis**  
  C. Varon, Bordeaux, France

- **Roadmap to eliminate Gastric cancer in Japan,**  
  M. Asaka, Sapporo, Japan

19.00 hrs  Networking Mixer
08.30 – 09.30 hrs
Opening conferences
Room: Aula Magna
Chair: J. Gisbert, Spain
C. O’Morain, Ireland
Speaking Time: 17’+3’
Structure of the proton-gated urea channel
H. Luecke, Irvine, CA, United States
STAT3 in gastric cancer
A. Giraud, Parkville, Australia
Role of CagY in the functional plasticity of H. pylori type 4 secretion system
J. Solnick, Davis, CA, United States

09.30 – 11.00 hrs
Symposium: Steps towards gastric cancer
Room: Aula Magna
Chair: A. Axon, United Kingdom
A. G. McNicholl, Spain
Speaking Time: 17’+3’
Epidemiological aspects of preneoplastic lesions
C.A. Gonzalez, Barcelona, Spain
Endoscopic assessment of preneoplastic lesions
M. Areia, Coimbra, Portugal
Phenotypes, biology, and Gastric cancer risk of of gastric metaplasia(s)
M. Rugge, Padova, Italy
Role of microRNA and cancer stem cells in gastric carcinogenesis
H. Suzuki, Tokyo, Japan

11.00 – 11.30 hrs
Coffee break
11.30 – 13.00 hrs  Workshop 1. Molecular Genetics & Virulence Factors
Room:  Aula Magna

Chair:  L. Engstrand, Sweden
A. Lanas, Spain

Speaking time:  12’+3’

W1.5  LRP-1 mediates autophagy and apoptosis caused by H. pylori vacuolating cytotoxin, VacA
T. Hirayama¹, M. Nakano¹, M. Noda², K. Yahiro²;
¹Nagasaki Univ., Nagasaki, Japan, ²Chiba Univ., Chiba, Japan.

W1.1  Chromosome painting in silico in a bacterial species reveals fine population structure
K. Yahara¹², Y. Furuta², K. Oshima³, M. Yoshida³, T. Azuma³, M. Hatton⁴, I. Uchiyama⁵, I. Kobayashi⁶;¹
¹Department of Medical Genome Sciences, Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan, ²Institute of Medical Science, University of Tokyo, Tokyo, Japan, ³Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany, ⁴Department of Computational Biology, Graduate School of Frontier Sciences, University of Tokyo, Kashiwa, Japan, ⁵Department of Gastroenterology, Graduate School of Medicine, Kobe University, Kobe, Japan, ⁶Laboratory of Genome Informatics, National Institute for Basic Biology, Okazaki, Japan.

W1.2  Genomes of H. pylori from India and Malaysia and the systems epidemiology at the anvil
N. Kumar¹, J. Vadivelu², N. Ahmed³;
¹Department of Biotechnology and Bioinformatics, University of Hyderabad, Hyderabad, India, ²Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

W1.3  Bacteriophage genes within genomes of H. pylori clinical isolates
A. Timóteo¹², P. Lehours³, M. Oleastro³, J. M. B. Vítor³, T. T. Perets³, Y. Niv³, F. Mégraud³, F. F. Vale¹⁷;³
¹Faculdade de Engenharia - Universidade Católica Portuguesa, Sintra, Portugal, ²Faculdade de Ciências da Universidade de Lisboa, Lisboa, Portugal, ³Université Bordeaux Segalen, INSERM U853, Bordeaux, France, ⁴Instituto Nacional de Saúde Dr Ricardo Jorge, Lisboa, Portugal, ⁵IMed.UL. Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal, ⁶Rabin Medical Center – Beilinson Hospital, Petah Tikva, Israel, ⁷Centro de Estudos do Ambiente e do Mar (CESAM/FCUL) – Faculdade de Ciências da Universidade de Lisboa, Lisboa, Portugal.

W1.4  H. pylori CagA directs gastric intestinal metaplasia by inducing stemness-related reprogramming factors
M. Hatakeyama, Y. Fuji;
Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

W1.6  Phosphorylation of bacterial effector CagA may be required for the induction of molecules involved in extracellular matrix remodeling in H. pylori experimental in vitro infection of gastric epithelial cells
I. Sougleri, K. Papadakos, A. F. Mentis, D. N. Sgouras;
Laboratory of Medical Microbiology, Hellenic Pasteur Institute, Athens, Greece.

13.00 – 13.30 hrs  Lunch
11.30 – 13.00 hrs  Workshop 2. Epidemiology and Pediatrics  
*Room:* Pagoda

*Chair:* L. Andersen, Denmark  
M.J. Martinez, Spain

*Speaking time:* 12'+3'

**W2.1**  
**H. pylori** colonization rate in children is highly variable among different ethnic groups in Western populations: the Generation R study  
W. J. den Hollander1, I. L. Holster1, B. van Gilst1, A. J. van Vuuren1, V. W. Jaddoe1, G. I. Perez-Perez2, M. J. Blaser3, H. A. Moll1, E. J. Kuipers1;  
1Erasmus MC University Medical Center, Rotterdam, Netherlands, 2New York Langone Medicine Center, New York, NY, United States.

**W2.2**  
The changing prevalence of **H. pylori** infection in dyspeptic patients from Budapest, Hungary: a retrospective endoscopic study, 1997-2012  
G. M. Buzás1, G. Lotz2, F. Schneider3, J. Józan4;  
1Ferencváros Health Center, Gastroenterology, Budapest, Hungary, 22nd Institute of Pathology, Semmelweis University, Budapest, Hungary, 3Cell Diagnostics Ltd, Budapest, Hungary, 4Institute of Physiology, Semmelweis University, Budapest, Hungary.

**W2.3**  
Reinfection after Successful Eradication of **H. pylori** in three different populations in Alaska  
M. G. Bruce1, D. Bruden1, J. Morris1, A. Reasonover1, F. Sacco2, D. Hurlburt1, T. Hennessy1, J. Gove3, A. Parkinson1, G. Sahagun1, P. Davis2, J. Klejka3, B. McMahan4;  
1Centers for Disease Control and Prevention, Anchorage, AK, United States, 2The Alaska Native Medical Center, Anchorage, AK, United States, 3Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium, Anchorage, AK, United States, 4Internal Medicine Associate INC, Anchorage, AK, United States, 5Liver Disease and Hepatitis Program, Division of Community Health Services, Anchorage, AK, United States.

**W2.4**  
Low efficacy of rescue treatments for **H. pylori** eradication in children after failure of a first sequential regimen  
N. Genis, A. Salame, E. Lenga, T. Mahler, M. Scaillon, S. Cadran, P. Bontems;  
Queen Fabiola Children’s University Hospital, Université Libre de Bruxelles, Brussels, Belgium.

**W2.5**  
String test utility to obtain **H. pylori** and perform antimicrobial susceptibility. A 13 year experience  
M. Montes1, M. Fernández-Reyes1, Y. Salicio1, A. Cosme2, L. Bujanda2,3, E. Pérez-Trallero1,2;  
1Microbiology Department, Hospital U. Donostia, Donostia-San Sebastián, Spain, 2Gastroenterology Department, Hospital U. Donostia, Donostia-San Sebastián, Spain, 3Faculty of Medicine, University of the Basque Country, UPV/EHU, Donostia-San Sebastián, Spain.

**W2.6**  
A new Approach as a non-invasive molecular method to detect **H. pylori** and determine clarithromycin and levofloxacin susceptibility: Stool Genotype HelicoDR  
T. Becerikli2, Ö. Yılmaz1, E. Demiray-Gürbüz1, S. Saroğlu2, M. Soytürk2, H. Ellidokuz4, I. Şimşek3;  
1Dokuz Eylül University, Faculty of Medicine, Department of Pathology, İzmir, Turkey, 2Dokuz Eylül University, Faculty of Medicine, Department of Gastroenterology, İzmir, Turkey, 3Dokuz Eylül University, Faculty of Medicine, Department of Medical Informatics and Biostatistics, İzmir, Turkey.
13.30 – 14.30 hrs  Poster Rounds

The following posters will be discussed with the authors

**Group 1:**  P01. Microbiology, P02. Molecular Genetics & P03. Virulence Factors and Pathogenesis

**Chair:**

P01.01 - P02.12:  C. Varon, France  
T. Alarcon, Spain

P02.13 - P03.08:  P. Lehours, France  
L. Engstrand, Sweden

P03.09 - P03.20:  N. Ahmed, India  
Y. Yamaoka, Japan

**Group 2:**  P04. Epidemiology and transmission, P09. Paediatric issues & P10. Diagnosis

**Chair:**

P04.01 - P04.18:  V. Mahachai, Thailand  
F. di Mario, Italy

P09.01 - P10.07:  M.J. Martinez, Spain  
L.V. Coelho, Brazil

P10.08 - P10.21:  P. Urruzuno, Spain  
Y. Niv, Israel

**Group 3:**  P13. Drug resistance & P15. Probiotics

**Chair:**

P13.01 - P13.22 & X. Calvet, Spain
P15.01. P15.07:  A. Gasbarrini, Italy
14.30 – 16.00 hrs  Symposium: Treatment of *H. pylori* infection – Beyond antibiotherapy

*Room:* Aula Magna

*Chair:* J. Molina Infante, Spain
T. Rokkas, Greece

*Speaking Time:* 17’+3’

**How to predict the outcome of an *H. pylori* therapy**  
*D. Graham, Houston, TX, United States*

**Vaccine – problems and perspectives**  
*S. Moss, Providence, RI, United States*

**Vaccine – current clinical results**  
*P. Malfertheiner, Magdeburg, Germany*

**Phototherapy – Bringing new light in therapy**  
*D. Garcia-Fresnadillo, Madrid, Spain*

16.00 – 16.30 hrs  Coffee break
16.30 – 18.00 hrs  Workshop 3. Treatment and Drug Resistance

Room: Aula Magna

Chair: F. Bazzoli, Italy
X. Calvet, Spain

Speaking Time: 12’+3’

W3.1 Effect of dosing schedules of amoxicillin on eradication rates of *H. pylori* by triple therapy with PPI, amoxicillin and clarithromycin or metronidazole

*Furuta T., Sugimoto M., Uotani T., Sahara S., Ichikawa H.*
Hamamatsu University School of Medicine, Hamamatsu, Japan.

W3.2 The molecular basis of inactivation of metronidazole resistant *H. pylori* by polyethyleneimine (PEI) functionalized zinc oxide (ZnO) nano-particles

*Bhattacharya S., Chakraborti S., Chakrabarti P., Chowdhury R.*
1Indian Institute of Chemical Biology, Kolkata, India, 2Bose Institute, Kolkata, India.

W3.3 Sequential and Concomitant treatments in *H. pylori* eradication: A network meta-analysis

*McNicholl A. G., Nyssen O. P., Gisbert J. P.*
La Princesa University Hospital, IP and CIBEREHD, Madrid, Spain.

W3.4 Sequential versus triple therapy for the treatment of *H. pylori*: a nationwide study

*Kim J. S., Kim B., Ji J., Lee B., Choi H.*
1Incheon St. Mary’s Hospital, Incheon, Korea, Republic of, 2Incheon St. Mary’s Hospital, Incheon, Korea, Democratic People’s Republic of.

W3.5 Clarithromycin for first-line treatment of *H. pylori* infection in high antibiotic resistance regions: better testing antimicrobial susceptibility before treating

*Martos M., Cosme A., Montes M., Ibarra U., Mendarte M., Sarasqueta C., Bujanda L.*
Hospital Universitario Donostia, San Sebastián, Spain.

W3.6 Does the Maastricht IV consensus report on *H. pylori* eradication have any implications in a South-European Country?

*Almeida N. M., Romãozinho J. M., Donato M. M., Luxo C., Cardoso O., Cipriano M. A., Marinho C. M., Sofia C.*
1Coimbra University Hospital, Coimbra, Portugal, 2Faculty of Medicine, Coimbra, Portugal, 3Faculty of Pharmacy, Coimbra, Portugal.

20.00 hrs  EHSG Networking Dinner in the Faena Madrid (Ticket required)
16.30 – 18.00 hrs

**Workshop 4. Other Helicobacters and Animal Models**

**Room:** Pagoda

**Chair:** T. Alarcon, Spain
J. Solnick, United States

**Speaking Time:** 12’+3’

**W4.1**

Urokinase plasminogen activator receptor (uPAR) is induced in gastric epithelial cells in response to *H. pylori* infection in a C57BL/6 mouse model

**W. Alpizar-Alpizar**1,2, M. E. Skindersø3, L. Rasmussen4,5, I. J. Christensen2, I. K. Lund2, O. D. Laerum2, K. A. Krogfelt1, L. P. Andersen4,5, M. Ploug2;
1Centre for Research on Microscopic Structures (CIEMic), University of Costa Rica, San Jose, Costa Rica, 2The Finsen Laboratory, Copenhagen University Hospital, Copenhagen, Denmark, 3Department of Microbiology and Infection Control, Statens Serum Institute, Copenhagen, Denmark, 4Department of Infection Control, Copenhagen University Hospital, Copenhagen, Denmark, 5Department of Clinical Microbiology, Copenhagen University Hospital, Copenhagen, Denmark.

**W4.2**

Pathogenic Properties of Enterohepatic *Helicobacter* spp. Associated with Intestinal Adenocarcinoma in Rhesus Macaques

K. Lertpiriyapong1, Y. Feng1, L. Handt2, T. W. Mitchell2, K. Lodge2, Z. Shen1, F. Dewhirst2, J. G. Fox1;
1Massachusetts Institute of Technology, Cambridge, MA, United States, 2The Forsyth Institute, Cambridge, MA, United States.

**W4.3**

Oral glutathione supplementation reduces *Helicobacter suis* - related gastric pathologies in a Mongolian gerbil model

E. De Bruyne, R. Ducatelle, A. Smet, F. Pasmans, F. Haesebrouck, B. Flahou;
Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.

**W4.4**

The gyrA gene: a pertinent target for *Helicobacteraceae* species taxonomy

A. Ménard1,2, A. Buissonnière1,2, V. Prouzet-Mauléon1,2, F. Mégraud1,2;
1Université de Bordeaux, Centre National de Référence des Helicobacters et Campylobacters., F33076 Bordeaux, France, 2INSERM U853, F33076 Bordeaux, France.

**W4.5**

Parkinson’s disease and *Helicobacter suis*: pigs, pork or transmission of human-adapted H. suis-like bacteria?

F. Haesebrouck1, A. Smet1, B. Flahou1, C. Blaecher1, F. Pasmans1, R. Ducatelle1, I. Bjarnason1, A. J. Lawson1, A. Charlet1,2, D. Taylor1,2, C. Weller1, R. J. Dobbs1,2,3, S. M. Dobbs1,2,3;
1Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium, 2Department of Gastroenterology, King’s College Hospital, London, United Kingdom, 3Laboratory of Gastrointestinal Pathogens, Public Health England, London, United Kingdom, 4Statistics Unit Centre for Infections, Public Health England, London, United Kingdom, 5Pharmaceutical Sciences, King’s College, London, United Kingdom, 6Maudsley Hospital, London, United Kingdom.

**W4.6**

Analysis of *Helicobacter* spp. Specific Antibodies with Multiplex Serology

J. Butt1, A. Michel1, M. Willhauck-Fleckenstein1, W. Nicklas2, J. G. Fox3, M. Pawlita4;
1Infection and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany, 2Microbiological Diagnostics, German Cancer Research Center (DKFZ), Heidelberg, Germany, 3Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA, United States.

20.00 hrs

**EHSG Networking Dinner in the Faena Madrid** (Ticket required)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 – 10.00 hrs</td>
<td>Symposium: Animal models for Helicobacter infection</td>
</tr>
<tr>
<td>Room:</td>
<td>Aula Magna</td>
</tr>
<tr>
<td>Chair:</td>
<td>B. Flahou, Belgium</td>
</tr>
<tr>
<td></td>
<td>A. Giraud, Australia</td>
</tr>
<tr>
<td>Speaking Time:</td>
<td>17’+3’</td>
</tr>
<tr>
<td></td>
<td>Mice models of gastric carcinoma</td>
</tr>
<tr>
<td></td>
<td><em>J. Fox, Boston, MA, United States</em></td>
</tr>
<tr>
<td></td>
<td>Mouse model of gastric MALT lymphoma</td>
</tr>
<tr>
<td></td>
<td><em>P. Lehours, Bordeaux, France</em></td>
</tr>
<tr>
<td></td>
<td>The Mongolian gerbil model</td>
</tr>
<tr>
<td></td>
<td><em>Y. Yamaoka, Oita, Japan</em></td>
</tr>
<tr>
<td></td>
<td>Animal models of gastric non-<em>H. pylori</em> Helicobacter infection</td>
</tr>
<tr>
<td></td>
<td><em>B. Flahou, Ghent, Belgium</em></td>
</tr>
<tr>
<td>10.00 – 10.30 hrs</td>
<td>Coffee Break</td>
</tr>
</tbody>
</table>
### Workshop 5. Gastric Cancer and Pre-malignant Lesions

**Room:** Aula Magna

**Chair:** C. Gonzalez, Spain  
A. Ristimäki, Finland

**Speaking Time:** 12'+3'

**P07.03**  
**Gastric cancer in Thailand: A 15 years review**  
*R. Vilachone*<sup>1,2</sup>, V. Mahacha†<sup>2</sup>;  
<sup>1</sup>Gastroenterology Unit, Department of Medicine, Thammasat University Hospital, Pathumthani, Thailand,  
<sup>2</sup>National Gastric Cancer and H. pylori Research Center, Bangkok, Thailand,  
<sup>†</sup>Division of Gastroenterology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand.

**W5.2**  
**Risk Factors and Clinical Outcomes for 327 Patients with Gastric Cancer Identified by Screening Endoscopy: Retrospective Case-control Study**  
University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of.

**W5.3**  
**Incisura angularis represents the more severe atrophic and chronic inflammatory changes compared to antrum mucosa and characterized by higher interobserver agreement**  
*S. Isajevs*<sup>1,2,3</sup>, I. Liepniece-Karele<br>†<sup>1,2,3</sup>, D. Janciauskas<sup>4</sup>, G. Moisejevs<sup>1,2,5</sup>, K. Funka<sup>1</sup>, I. Kikuste<sup>6</sup>, A. Vanags<sup>6</sup>, I. Tolmanis<sup>6</sup>, M. Leja<sup>1,2,6</sup>;  
<sup>1</sup>Faculty of Medicine, University of Latvia, Riga, Latvia,  
<sup>2</sup>Riga East University Hospital, Riga, Latvia,  
<sup>3</sup>Academic Histology Laboratory, Riga, Latvia,  
<sup>4</sup>Lithuanian University of Health Sciences, Faculty of Medicine, Kaunas, Lithuania,  
<sup>5</sup>Riga Stradins University, Riga, Latvia,  
<sup>6</sup>Digestive Diseases centre GASTRO, Riga, Latvia.

**P18.02**  
**The role of autophagy in H. pylori-related gastric cancer**  
*N. Castano Rodriguez*<sup>1</sup>, N. O. Kaakoush<sup>1</sup>, K. Goh<sup>2</sup>, K. Fock<sup>3</sup>, D. Forman<sup>4</sup>, H. Mitchell<sup>5</sup>;  
<sup>1</sup>The University of New South Wales, Sydney, Australia,  
<sup>2</sup>University of Malaya, Kuala Lumpur, Malaysia,  
<sup>3</sup>Changi General Hospital, Singapore, Singapore,  
<sup>4</sup>International Agency for Research on Cancer, Lyon, France.

**W5.5**  
**Ancestral origin and virulence markers of H. pylori strains and host genetic structure as predictors of gastric cancer (GC)**  
*D. M. Queiroz*<sup>1</sup>, *G. A. Rocha*<sup>2</sup>, A. M. C. Rocha<sup>1</sup>, F. F. Melo<sup>1</sup>, C. A. Oliveira<sup>1</sup>, M. M. D. A. Cabral<sup>1</sup>, R. P. A. Cunha<sup>1</sup>, A. D. Gomes<sup>1</sup>, C. Anacleto<sup>1</sup>, K. N. Teixeira<sup>1</sup>, C. G. M. C. Trant<sup>1</sup>, R. Calixto<sup>1</sup>, E. M. Tarazona-Santos<sup>1</sup>, F. S. G. Kehdy<sup>1</sup>, K. S. Brito<sup>1</sup>, R. S. Coimbra<sup>1</sup>, A. A. M. Lima<sup>2</sup>;  
<sup>1</sup>Universidade Federal de Minas Gerais/Faculade de Medicina, Belo Horizonte, Brazil,  
<sup>2</sup>Universidade Federal do Ceará, Belo Horizonte, Brazil.

**W5.6**  
**Characterization of the gastric microbiota in patients with chronic gastritis and gastric carcinoma**  
*R. M. Ferreira*<sup>1</sup>, J. L. Costa<sup>1</sup>, C. Figueiredo<sup>1,2</sup>, J. C. Machado<sup>1,2</sup>;  
<sup>1</sup>IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal,  
<sup>2</sup>Department of Pathology and Oncology, Faculty of Medicine of the University of Porto, Porto, Portugal.
10.30 – 12.00 hrs  Workshop 6. Modulation of Inflammation and Immunity
   
   **Room:** Pagoda

   **Chair:** S. W. Lee, Korea
   J.C. Machado, Portugal

   **Speaking time:** 12'+3'

**W6.1**  
*H. pylori* and the risk of upper GI bleeding in NSAID and or low-dose ASA users.
C. Sostres¹, R. Benito¹, P. Carrera², M. Arroyo¹, M. Roncales¹, S. Hernandez-Díaz³, L. Garcia-Rodriguez⁴, A. Lanas¹,³,⁵;
¹HCU Lozano Blesa, Zaragoza, Spain, ²CiberEHD, Madrid, Spain, ³Oxford University, Oxford, United Kingdom, ⁴CEIFE, Madrid, Spain, ⁵Health Research Institute Aragón, Zaragoza, Spain, ⁶ciberEHD, Madrid, Spain.

**W6.2**  
Non steroidal Anti-Inflammatory Drugs (NSAIDs) do not alter mucin protein expression but may affect glycosylation in the stomach of gastric ulcer patients
Y. Niv¹, M. Cohen², M. Halpern¹, S. Morgenstern¹, D. Boltin¹, Z. Levi¹, S. Batra¹, S. B. Ho²;
¹Rabin Medical Center, Tel Aviv University, Petach Tikva, Israel, ²UCSD, San Diego, CA, United States

**W6.3**  
Therapeutic vaccination against *H. pylori*: neutralizing antibodies and T-cells
F. Anderl, C. Bolz, B. Kalali, D. H. Busch, M. Gerhard;  
Institut für medizinische Mikrobiologie, Technische Universität München, Munich, Germany.

**W6.4**  
The Interaction between *H. pylori* and Influenza A - Friends or Foes?
Massachusetts Institute of Technology, Cambridge, MA, United States.

**P05.3**  
Isopropranol extracts of *Artemisia* imposed anti-oxidative and anti-inflammatory activities as well as cytoprotective actions against *H. pylori* infection
K. Hahm, J. Park, Y. Han, S. Hong, W. Kim, E. Kim;
CHA University, Seongnam, Korea, Republic of.

**W6.6**  
Mitochondria biogenesis is induced in response to *H. pylori* infection in a partially VacA-dependent manner
L. Chatre¹, J. Fernandes³, V. Michel², M. Ricchetti³, E. Touati³;
¹Institut Pasteur, Unit of Molecular Genetic of Yeast, Paris, France, ²Institut Pasteur, Unit of Helicobacter Pathogenesis, Paris, France.

12.00 – 12.30 hrs  Lunch
12.30 – 13.30 hrs  Poster Rounds

The following posters will be discussed with the authors

**Group 4:**  P11. Clinical Trials and Novel Treatments

Chair:  P11.01 - P11.16:  A. Lanas, Spain
        A. O'Connor, Ireland
        P11.17 - P4.31:  J. Molina-Infante, Spain
        H. Suzuki, Japan
        P11.32 - P11.46:  M. Areia, Spain
        A. Perez-Aisa, Spain

**Group 5:**  P05. Inflammation and host response, P06. Pathology and pathophysiology,
P07. Preneoplastic and neoplastic diseases & P18. *H. pylori* and Gastric Cancer

Chair:  W6.5 & P05.01 - P06.07:  L. Andersen, Denmark
        M. Selgrad, Germany
        W5.1 & P07.01 - P07.10:  M. Rugge, Italy
        M. Leja, Latvia
        P18.01 - P18.19:  S. Moss, United States
        C. Gonzalez, Spain


Chair:  P08.01 - P08.07 & P14.01 - P14.02 & P16.01 - P16.11:  J. Fox, United States
        F. Franceschi, Italy

13.30 – 15.00 hrs  Symposium: *The Healthy Stomach Initiative*

**Aula Magna**

Chair:  P. Malfertheiner, Germany
        F. Mearin, Spain

Speaking Time:  17’+3’

*The asymptomatic stomach*  
A. O’Connor, Dublin, Ireland

*The infected stomach*  
F. Bazzoli, Bologna, Italy

*Screening for gastric cancer during screening for CRC*  
M. Selgrad, Magdeburg, Germany

*Mass eradication of *H. pylori*  
J.M. Liou, Taipei, Taiwan
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
<th>Chair</th>
<th>Speaking Time</th>
<th>Details</th>
</tr>
</thead>
</table>
| 15.00 – 15.30 hrs | **Special Lecture**                                                    | Aula Magna   | J. Pajares, Spain  
M. Quina, Portugal | 25’+5’        | *H. pylori* therapy – Beyond Maastricht 4  
J. Molina-Infante, Cáceres, Spain                      |
| 15.30 – 16.00 hrs | **Coffee break**                                                      |              |                                                 |               |                                                                        |
| 16.00 – 16.45 hrs | **Debate: Should we use pepsinogen for the screening of gastric cancer?** | Aula Magna   | D. Graham, United States  
M. Leja, Latvia                        | 17’+3’        | *Yes:* F. di Mario, Trevise, Italy  
*No:* X. Calvet, Barcelona, Spain                    |
| 16.45 – 17.45 hrs | **Closing Conferences**                                               | Aula Magna   | G. Gasbarrini, Italy  
J. Gisbert, Spain                          | 17’+3’        | *Iron deficiency anemia and gastric carcinogenesis*  
*M.R. Amieva, Palo Alto, CA, USA*  
*Autophagy and H. pylori*  
*N. Jones, Toronto, Canada*  
*Awarding of the Marshall & Warren Medal to Masahiro Asaka, Sapporo, Japan* |
| 17.45 – 18.00 hrs | **Presentation of the next meeting in Rome (G. Gasbarrini)**           | Aula Magna   |                                                 |               | *Closing remarks*                                                      |
SCIENTIFIC INFORMATION, POSTER SCHEDULE

Oral Presentations

Speaking Time
The chairpersons of your session will be strict in allowing no more than the time allotted to your presentation. Remember to allow some time for the changeover of speakers and chairperson’s introduction, and for questions and discussion. Make yourself known to the chairpersons and/or the technician in your session room before the beginning of the session.

Projection and Technical Setting
All rooms are equipped with a (Windows) PC and data projector for Power Point presentation only.

Handing in Your Presentation:
It must then be handed over to the technician of the according lecture room in a break at least 1 hour before your talk either via USB-Memory Stick or CD-Rom (30 minutes for talks in the first morning sessions).

Presentation Format - Technical Issues:
The lecture rooms are exclusively equipped with Windows-PCs (no Macintosh machines). Please bring a CD-ROM, or USB drive, formatted for Windows® (PC). You may want to carry a second disk or a USB-memory stick as a back-up in case there is any technical problem. File Format: Microsoft® Power Point™ presentation formatted for Windows® (PC) only. (Operating system: Windows XP®). Maximum Resolution: XGA (1024 x 768 pixel)

Poster Presentations

ATTENTION: Posters are on display for one day only. Posters need to be taken off by the author at the end of the day. Posters not removed until then will be removed by the staff. Posters will be discarded, and neither kept nor sent to the authors. Please note that the organisers cannot assume any liability for loss, theft or damage of posters displayed in the poster area.

You will find your poster board number in the author index of the abstract book, which you have received at the registration desk.

The presence at the poster of one of the authors is mandatory during the following times:

**Friday, September 13, 2013, 13.30 – 14.30 hrs**
Group 1: P01. Microbiology, P02. Molecular Genetics, P03. Virulence Factors and Pathogenesis
Group 2: P04. Epidemiology and transmission, P09. Paediatric issues, P10. Diagnosis

Mounting of the posters in Rounds 1-3 is possible on Friday, September 13, 2013 from 8.00 hrs
Removal on Friday, September 13, 2013, from 16.30 hrs.
Saturday, September 14, 2013, 12.30 – 13.30 hrs
Group 4: P11. Clinical Trials and Novel Treatments
Group 5: P05. Inflammation and host response
        P06. Pathology and pathophysiology,
        P07. Preneoplastic and neoplastic diseases
        P18. *H. pylori* and Gastric Cancer
Group 6: P08. Oesophageal and extradigestive diseases
        P16. Other Helicobacters

Mounting of the posters in Rounds 4-6 is possible on Saturday, September 14, 2013 from 8.00 hrs
Removal on Saturday, September 14, 2013, from 15.30 hrs.

Format
The usable surface on the poster board is 90 cm width x 150 cm height (portrait format). Adhesive material will be made available.
GENERAL INFORMATION

In alphabetical order.

Badges
Participants should collect name badges from the conference registration desks. As only registered participants will be permitted to attend the Scientific Sessions, the Exhibition and poster areas, you are kindly asked to wear your badge when entering the congress venue.

Cancellations and Refunds
Notice of cancellation had to be made in writing by email or fax to the Congress Office.
The policy for refunding registration fees is as follows:
Written cancellation received:
- Before August 15, 2013: 75% refund
- After August 15, 2013: no refund
The date of the email or fax ID is the basis for considering refunds. Refunds will be made after the congress.

Certificate of Attendance
Confirmations of attendance will be issued at the registration desk.

Cash Dispensers
ATMs are widely available in Madrid. Local currency (Euro) can also be obtained from banks and exchange bureaus.

CME Credits
The “XXVIth International Workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation and Gastric Cancer” was granted 12 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

Coffee Breaks and Lunch
During the session breaks refreshments (coffee, tea, and water) will be served free of charge to participants wearing name badges.
Lunch tickets for Friday and Saturday had to be pre-ordered and cannot be purchased on site. Price per day: EUR 14.-. Lunch tickets are not refundable.

Congress Venue
Facultad de Medicina de la Universidad Autónoma de Madrid
“Decanato de Medicina”/Medical School Administration Building
Calle del Arzobispo Morcillo 4
28029 Madrid
Spain
Bus connection: Lines 67 and 124.

Currency
The official currency of Spain is the Euro (EUR).
1 EUR = 1,32 USD = 0,85 GBP = 130 JPY = 1,23 CHF = 7,45 DKK = 1,48 AUD
as per date of printing.

Electricity Supply
230V - 50Hz; C, F & L plugs type. Connectors can be obtained from your hotel reception or electronic stores.

GSM cell phone roaming
GSM cell/mobile phone roaming is available without any problems for all major international providers. It is advisable to inquire at your provider which roaming company in Spain offers the cheapest tariffs.

Internet
You will find Internet cafés throughout the city. WIFI is available, please ask for a code at the registration desk.

Language
The official language of the congress is English (no simultaneous translation).
GENERAL INFORMATION

Liability
In registering for the EHSG 2013 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements in respect of health and travel. Furthermore, the organisers cannot assume any liability for changes in the programme due to external or unforeseen circumstances and force majeure.

Opening hours of the registration desk at the Congress Centre
Thursday, September 12, 2013: 12.00 – 18.00 hrs
Friday, September 13, 2013: 08.00 – 18.00 hrs
Saturday, September 14, 2013: 08.00 – 18.00 hrs

Poster Removal
The organisers cannot assume any liability for loss or damage of posters displayed in the poster area. Posters that were not removed after the end of the respective day of display, will be removed and will not be kept nor mailed to the author after the meeting.

Presentations
All presenters should hand in their electronic presentation to the technician of the according lecture room in a break at least 1 hour before your talk either via USB-Memory Stick or CD-Rom (30 minutes for talks in the first morning sessions).

Safety - Crime
Visitor safety is generally adequate, like in any other major European city. You can walk everywhere using common sense. Pick pocketing in heavily visited tourist zones or in public transport lines might be a concern.
Unfortunately experience has shown that some basic precautionary measures should always be kept in mind in any city:
- Do not carry important items like flight tickets, passports etc. with you when visiting the conference or strolling through the city, leave them in the hotel safe during your stay. Rather carry a Xerox copy of your passport or an identity card with you.
- Try not to carry all documents, money, credit cards and other essential items and valuables in one bag. If it is lost or stolen, everything will be gone and might be difficult to replace on short notice, especially passports and visa to return to your country of residence.
- Take off your name badge when leaving the conference venue, it will make you easily identifiable as a tourist.

Smoking Policy
The EHSG 2013 Workshop is a “No-smoking-Conference”.

Staff
If you should have any questions, the congress staff will be pleased to help you.

Taxi
Taxis are available outside the airport terminal. Depending on traffic, expect up to 25 euros to any central location. Do not accept offers from drivers inside the terminal, since these are often illegal drivers and it is likely you will get ripped off.
There are many supplements to the basic fare, that may be applicable to your case. These include: 1.85 euros obligatory initial fare, 5 euros surcharge to/from airport, 2.50 euros surcharge to/from bus or train stations. All supplements are further increased at weekends or holidays. There is now no charge for suitcases, rucksacks or pets. Always ask for a receipt at the end of your journey in case the fare comes into dispute.

Weather
September in Madrid
- Average high: 26°C / 79°F
- Average low: 15°C / 59°F
- Average rainfall: 27 mm / 1 in
REGISTRATION DETAILS

Registration Fees

<table>
<thead>
<tr>
<th>Payment received</th>
<th>Before July 15, 2013</th>
<th>After July 15, 2013 and on site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular Participants</td>
<td>EUR 300.–</td>
<td>EUR 400.–</td>
</tr>
<tr>
<td>Young Scientists (&lt;35 years)</td>
<td>EUR 150.–</td>
<td>EUR 200.–</td>
</tr>
<tr>
<td>Students (&lt;30 years)</td>
<td>EUR 100.–</td>
<td>EUR 100.–</td>
</tr>
<tr>
<td>Company Representatives</td>
<td>EUR 450.–</td>
<td>EUR 550.–</td>
</tr>
<tr>
<td>Day Ticket</td>
<td>-</td>
<td>EUR 200.–</td>
</tr>
<tr>
<td>Networking Evening</td>
<td>EUR 50.–</td>
<td>EUR 50.–</td>
</tr>
</tbody>
</table>

Payment of Registration fees may be made either cash in Euro or by Credit Card (Diners Club, Mastercard and Visa).

Please note

The reduced registration fee was only applicable, if it has been credited to the congress account before the deadline. Registering before July 15, 2013 without performing an actual payment was not sufficient to benefit from the reduction.

What is covered by the registration fee?

• Admission to all scientific sessions and the exhibition
• Admission to the networking mixer
• Abstract book and programme
• 1 copy of “Year in Helicobacter 2013”
• Refreshments during coffee breaks

Cancellations

Notice of cancellation must have been made in writing by email or fax to the Congress Office. The date of the email/fax ID was the basis for considering refunds.

Registration fees may be refunded after the workshop as follows:
- Cancellation received before August 15, 2013: 75% refund
- after August 15, 2013: no refund

SOCIAL EVENTS

Thursday, September 12, 2013, 19.00 hrs
Networking Mixer at the Casa de la Panaderia at Plaza Mayor (Main Square)
Free for registered participants, however registration for this event is mandatory.
Metro: Opera (Lines 2, 5 & R) or Puerta del Sol (Lines 1, 2, 3, C-3 & C-4)

Friday, September 13, 2013, 20.00 hrs
EHSG Networking Evening in the Faena Madrid
Price: EUR 50.-
Ticket is required and will be checked at the entrance.
Metro: Atocha (Line 1)